Anti-amyloid antibodies in
Alzheimer’s disease: what did clinical
trials teach us?
Danko Jeremic, Lydia Jiménez-Díaz*
, Juan D. Navarro-López*
NeuroPhysiology & Behavior Lab, University of
Castilla-La Mancha, Biomedical Research Center
(CRIB), School of Medicine of Ciudad Real, Ciudad
Real, Spain
Online:2025-04-15
Published:2024-07-01
Contact:
Juan D. Navarro-López, PhD, Juan.Navarro@uclm.es; Lydia Jiménez-Díaz, PhD, Lydia.Jimenez@uclm.es.
Supported by:
This work was supported by grants PID2020–115823-
GB100 funded by MCIN/AEI/10.13039/501100011033,
and SBPLY/21/180501/000150 funded by JCCM/ERDF -
A way of making Europe, and 2022-GRIN-34354 grant
by UCLM/ERDF intramural funding to LJD and JDNL.
DJ held a predoctoral fellowship granted by UCLM/ESF
“Plan Propio de Investigación.”
Danko Jeremic, Lydia Jiménez-Díaz, Juan D. Navarro-López. Anti-amyloid antibodies in
Alzheimer’s disease: what did clinical
trials teach us?[J]. Neural Regeneration Research, 2025, 20(4): 1092-1093.